What the BioWeapon Industry Inserted in SARS-CoV-2


After one year, even Wall Street Journal cannot afford to hide it any more: SARS-CoV-2 is laboratory-designed, with evil intention. Quay and Muller pinpoint the ‘double CGG’ addition to the virus, first discovered by French virologist Bruno Coutard:

Although the double CGG is suppressed naturally, the opposite is true in laboratory work. The insertion sequence of choice is the double CGG. That’s because it is readily available and convenient, and scientists have a great deal of experience inserting it. An additional advantage of the double CGG sequence compared with the other 35 possible choices: It creates a useful beacon that permits the scientists to track the insertion in the laboratory. Now the damning fact. It was this exact sequence that appears in CoV-2. (…) When the lab’s Shi Zhengli and colleagues published a paper in February 2020 with the virus’s partial genome, they omitted any mention of the special sequence that supercharges the virus or the rare double CGG section. Yet the fingerprint is easily identified in the data that accompanied the paper. Was it omitted in the hope that nobody would notice this evidence of the gain-of-function origin? But in a matter of weeks virologists Bruno Coutard and colleagues published their discovery of the sequence in CoV-2 and its novel supercharged site. Double CGG is there; you only have to look. They comment in their paper that the protein that held it “may provide a gain-of-function” capability to the virus, “for efficient spreading” to humans.

It is quite a coincidence: Bruno Coutard is affiliated to the same IHU in Marseille as the famous expert in infectious diseases, prof. Didier Raoult. Tellingly, these two professors have no joint publications. If there were any truth in the gossip that Raoult signs all papers from his Institute, at least here we have the exception. Now what exactly did Coutard discover in early 2020? The figure below is from his publication entitled The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.


Nucleotides are the very programming digits of biology. Where in digital computers these digits are called 0 and 1, in biology they are called A,C,G and T. Three of them form a triplet. Every triplet codes for a single amino acid, which is the biological construction unit of proteins: proteins are strings of amino acids. The latter come in many variants, twenty of which are used by the biological correspondence table between code (nucleotide triplets) and construction unit (amino acids). The triplet CCG codes for the amino acid Arginine (Arg, or R). The two Arginine molecules are part of the furin-like sequence PRRA (Proline-Arginine-Arginine-Alanine), which serves a directly identifiable biological purpose (cleavage site), and is not found in any natural SARS or MERS variant. The horizontal scale gives the number of mutations of the daughter species (to the right of a bifurcation) with respect to the parent species (to the left of a bifurcation). What makes PRRA quite special, is that it did not result from the mutation of previously existing nucleotides, but from the addition of 12 of these nucleotides. Although a natural process can never be excluded, experts confirm that they are highly unlikely to produce this specific addition.


Bruno Coutard and coworkers identified a peculiar furin-like cleavage site in the Spike protein expressed by patients affected by Covid-19. This cleavage site lacks in all other SARS-like CoVs, and has functional consequences in the viral cycle. Bruno Coutard is an expert in the field: ever since the outbreak of the 2004 severe acute respiratory syndrome (SARS), he has been investigating enzymatic activity in SARS and MERS (Middle East Respiratory Syndrome).


Estimated equilibrium configuration of the Furin enzyme. Some proteins are inactive when they are first synthesized, and must have sections removed in order to become active. Furin cleaves these sections (at the PRRA sequences), thereby activating the proteins.